Participants 60 150 5
in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy
Participants 317 426 6
n postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT).
Participants 435 878 13
Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin were accumulated and prostectively studied in this study. The patients were randomly divided into two groups. Two hundred and twenty-eight patients were treated with concurrent capecitabine and radiotherapy (Cap-CRT), and 172 patients were treated with capecitabine and oxaliplatin plus radiotherapy (Cap-Oxa-CRT).
Participants 2092 2117 3
patients with AA genotype
Participants 2443 2499 3
in postoperative stage II and III rectal cancer patients
